ABVC BioPharma, Inc. (ABVC) | Investment Case

1. Company Snapshot

1.a. Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is based in Fremont, California.ABVC BioPharma, Inc.is a subsidiary of YuanGene Corporation.

Show Full description

1.b. Last Insights on ABVC

ABVC BioPharma's recent developments have been impacted by a lack of significant pipeline advancements and limited revenue growth. The company's reliance on licensing agreements, such as the $200,000 payment from OncoX, may not be enough to drive substantial growth. Additionally, the company's cash burn rate and limited cash reserves may pose a challenge, highlighting the need for further financing or strategic partnerships to support its clinical-stage pipeline.

1.c. Company Highlights

Last Price	2.41
Change Percentage	-4.74%
Open	2.53
Previous Close	2.53
Market Cap ( Millions)	35
Volume	76791
Year High	5.48
Year Low	0.4
M A 50	2.89
M A 200	2.16

FCF Yield	-5.90%
Dividend Yield	0.00%
ROE	-64.70%
Debt / Equity	11.54%
Net Debt / EBIDTA	-33.63%
Price To Book	4.65
Price Earnings Ratio	-13.48
Price To FCF	-16.95
Price To sales	43.77
EV / EBITDA	-10.13

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Dec -11

Source: globenewswire.com

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Oct -22

Source: globenewswire.com

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Aug -15

Source: globenewswire.com

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr -18

Source: globenewswire.com

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr -17

Source: globenewswire.com

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Apr -10

Source: globenewswire.com

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar -26

Source: globenewswire.com

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar -19

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

New Drugs and Medical Devices

Expected Growth: 12.4%

Growing demand for cancer and infectious disease treatments, increasing investment in R&D, and advancements in proprietary platforms VC/VS-01 and ABV-1501 are expected to drive ABVC BioPharma's growth.

7. Detailed Products

ABV-1505

A proprietary, patented, and clinically-tested medical device for treating neurological disorders, including ADHD, anxiety, and depression.

ABV-1701

A novel, patented, and clinically-tested pharmaceutical for treating cancer, including pancreatic, lung, and breast cancer.

ABV-1504

A proprietary, patented, and clinically-tested medical device for treating chronic pain, including fibromyalgia and neuropathic pain.

ABV-1601

A novel, patented, and clinically-tested pharmaceutical for treating infectious diseases, including COVID-19 and influenza.

8. ABVC BioPharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for ABVC BioPharma, Inc. is medium due to the presence of alternative treatments and therapies for cancer and other diseases.

Bargaining Power Of Customers

The bargaining power of customers for ABVC BioPharma, Inc. is low due to the company's specialized products and limited competition.

Bargaining Power Of Suppliers

The bargaining power of suppliers for ABVC BioPharma, Inc. is medium due to the company's dependence on a few key suppliers for raw materials and equipment.

Threat Of New Entrants

The threat of new entrants for ABVC BioPharma, Inc. is high due to the growing demand for biopharmaceuticals and the increasing number of new entrants in the market.

Intensity Of Rivalry

The intensity of rivalry for ABVC BioPharma, Inc. is high due to the competitive nature of the biopharmaceutical industry and the presence of established players.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	21.71%
Debt Cost	8.42%
Equity Weight	78.29%
Equity Cost	8.42%
WACC	8.42%
Leverage	27.73%

11. Quality Control: ABVC BioPharma, Inc. passed 2 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Verve Therapeutics

A-Score: 4.4/10

Value: 6.8

Growth: 4.3

Quality: 5.0

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

ABVC BioPharma

A-Score: 4.2/10

Value: 6.2

Growth: 4.4

Quality: 4.3

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

Jaguar Health

A-Score: 3.2/10

Value: 9.6

Growth: 5.9

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

BioXcel Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Veru

A-Score: 2.9/10

Value: 6.6

Growth: 0.9

Quality: 4.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

Gain Therapeutics

A-Score: 2.2/10

Value: 6.0

Growth: 1.6

Quality: 3.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

28.90%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.42%

ABVC BioPharma, Inc. - US00091F3047

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ABVC

1.c. Company Highlights

Lower Quality

Weak Momentum

Medium Volatility

More Volatile

Stable Momentum

Fairly Valued

Average Quality

Average Growth

Strong Momentum

Average Yield

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

New Drugs and Medical Devices

Expected Growth: 12.4%

7. Detailed Products

ABV-1505

ABV-1701

ABV-1504

ABV-1601

8. ABVC BioPharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: ABVC BioPharma, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.41$

Current Price

2.41$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA